---

Occupational Diseases — Pathology Notes (2nd Year MBBS)

---

Definition

---

Classification (Table)

---

General Pathogenesis of Pneumoconioses

1. Dust retention — determined by ambient dust concentration, duration of exposure, and effectiveness of mucociliary clearance (cigarette smoking significantly impairs clearance)
2. Particle size — most dangerous particles: 1–5 μm in diameter (reach terminal airways and alveolar sacs); particles >5–10 μm are filtered in upper airways; particles <0.5 μm move in and out of alveoli without significant deposition
3. Particle solubility & cytotoxicity — small, highly soluble injurious particles → rapid acute lung injury; larger insoluble particles → chronic fibrosis
4. Inflammasome activation — phagocytosis by macrophages activates the inflammasome → release of IL-1, IL-18 → recruitment of inflammatory cells → fibroblast activation → collagen deposition
5. Tobacco smoking — worsens ALL inhaled mineral dust diseases, most notably asbestos

---

1. Coal Workers' Pneumoconiosis (CWP)

Etiology

Spectrum of Disease

Clinical Features

• Usually benign with little lung function decline
• PMF → progressive pulmonary dysfunction, pulmonary hypertension, cor pulmonale
• No increased risk of lung carcinoma (distinguishes CWP from silicosis and asbestosis)
• Less than 10% of simple CWP progresses to PMF

---

2. Silicosis

Etiology

Pathogenesis

• Silica phagocytosed by macrophages → inflammasome activation → IL-1 and IL-18 release → inflammatory cell recruitment → interstitial fibroblast activation → collagen deposition
• Crystalline forms far more fibrogenic than amorphous forms
• Clay coating of silica in coal/hematite miners reduces toxicity
• Disease is progressive even after exposure stops

Morphology

• Early: Tiny, pale-to-black discrete nodules in hilar lymph nodes and upper zones of lung
• Progressive: Nodules coalesce into hard, collagenous scars
• PMF: Expansion and coalescence of lesions
• Hallmark histology: Central area of whorled collagen fibers with peripheral zone of dust-laden macrophages; weakly birefringent particles under polarized microscopy
• Eggshell calcification of hilar lymph nodes — radiographic hallmark
• May cavitate due to superimposed tuberculosis or ischemia

Clinical Features

• Onset: Slow and insidious (most common, 10–30 years); accelerated (<10 years); acute/rapid (months after intense exposure — accumulation of lipoproteinaceous material, resembles alveolar proteinosis)
• Chest X-ray: fine nodularity in upper zones
• Pulmonary function: normal or mildly reduced early; worsens with PMF
• Increased susceptibility to tuberculosis (silica inhibits macrophage killing of mycobacteria) — "silicotuberculosis"
• 2-fold increased risk of lung cancer

---

3. Asbestos-Related Diseases

Types of Asbestos

Asbestos-Related Diseases (6)

1. Asbestosis — parenchymal interstitial fibrosis
2. Localized pleural plaques (most common manifestation) or, rarely, diffuse pleural fibrosis
3. Recurrent pleural effusions
4. Lung carcinoma
5. Malignant mesothelioma (pleural and peritoneal)
6. Laryngeal cancer (± ovarian, colon)

Pathogenesis

• Fibers land at bifurcations of small airways and ducts, penetrate, and are directly toxic
• Macrophages phagocytose fibers → inflammasome activation → reactive oxygen species, proteases, cytokines, growth factors → generalized interstitial fibrosis
• Asbestos acts as both tumor initiator and tumor promoter via free radical generation (iron in fibers)
• Tobacco smoke carcinogens adsorb onto asbestos fibers → remarkable synergy for lung carcinoma

Morphology — Asbestosis

• Diffuse pulmonary interstitial fibrosis — distinguished from other ILD only by presence of asbestos bodies
• Asbestos bodies: Golden-brown, fusiform or beaded rods with translucent center — asbestos fiber coated with iron-containing proteinaceous material (ferruginous bodies)
• Fibrosis begins at lower lobes and subpleurally (unlike CWP/silicosis which start upper lobes)
• Progresses → honeycomb pattern → pulmonary hypertension, cor pulmonale

Morphology — Pleural Plaques

• Most common manifestation of asbestos exposure
• Well-circumscribed plaques of dense, often calcified collagen
• Anterior and posterolateral parietal pleura; over domes of diaphragm
• Usually asymptomatic; detected on X-ray

Clinical Features of Asbestosis

• Symptoms appear 10–20 years after first exposure (rarely <10 years)
• Dyspnea — first symptom (exertional → resting)
• Cough + sputum (usually due to smoking, not asbestosis itself)
• CXR: irregular linear densities in both lower lobes → honeycomb pattern
• May progress to respiratory failure, cor pulmonale, death

Cancer Risk

Family members of asbestos workers also have increased risk due to secondary exposure (asbestos fibers on clothing, etc.)

---

4. Caplan Syndrome

• Combination of pneumoconiosis (coal/silica/asbestos) + rheumatoid arthritis
• Large, well-defined, rapidly developing nodules (rheumatoid nodules) superimposed on simple pneumoconiosis
• Represents an immunologic reaction

---

5. Byssinosis

• Inhalation of cotton, flax, or hemp dust in textile manufacturing
• Organic dust-induced asthma
• "Monday morning tightness" — symptoms worst on first day back after weekend

---

6. Berylliosis

• Acute: Chemical pneumonitis
• Chronic: Beryllium granulomatosis — non-caseating granulomas; histologically identical to sarcoidosis — must be differentiated by occupational history
• Possible increased risk of lung carcinoma

---

Key Distinguishing Features (High-Yield Summary)

---

Sources

• Robbins Pathologic Basis of Disease (10th ed.) — Chapter 15 (Lung)
• Robbins & Kumar Basic Pathology — Chapter 11 (Lung)

---

Vitamin K — Complete Notes (2nd Year MBBS)

---

Overview

---

Forms of Vitamin K

---

Chemistry

• Fat-soluble vitamin (quinone derivative)
• Active functional form: hydroquinone (reduced form)
• Inactive oxidized form: vitamin K epoxide
• Recycling enzyme: Vitamin K Epoxide Reductase (VKOR) — converts inactive epoxide back to active hydroquinone

---

Biochemical Mechanism of Action

γ-Carboxylation Reaction

• γ-glutamyl carboxylase enzyme
• O₂ and CO₂
• Hydroquinone form of vitamin K (gets oxidized to epoxide during the reaction)

Why Gla Residues Matter

• Gla residues have two adjacent negatively charged carboxylate groups → excellent chelators of Ca²⁺ ions
• The protein-Ca²⁺ complex then binds to negatively charged phospholipid membranes on damaged endothelium and platelets
• This membrane attachment dramatically increases the rate of proteolytic activation of clotting factors (e.g., prothrombin → thrombin)

---

Vitamin K-Dependent Proteins

Procoagulant (Clotting Factors) — all synthesized in liver

Anticoagulant Proteins

• Protein C — inhibits Factors Va and VIIIa
• Protein S — cofactor for Protein C

Note: Vitamin K is required for both pro- and anticoagulant proteins. In early warfarin therapy, Protein C (short half-life) falls first → transient hypercoagulable state.

Bone and Other Proteins

• Osteocalcin — bone Gla protein; involved in bone mineralization
• Matrix Gla Protein (MGP) — inhibits vascular calcification

---

Dietary Requirement & Absorption

• Adult males: 120 μg/day (Adequate Intake)
• Adult females: 90 μg/day
• Absorption: Requires bile salts and dietary fat (fat-soluble vitamin); absorbed predominantly in the ileum
• Two major sources: dietary intake + gut bacterial synthesis

---

Vitamin K Cycle (VKOR Cycle)

Active hydroquinone (KH₂)
        ↓  [γ-glutamyl carboxylase + O₂ + CO₂]
  Glu → Gla (on clotting factors)
        ↓
Inactive vitamin K epoxide (KO)
        ↓  [VKOR — Vitamin K Epoxide Reductase]
Active hydroquinone (KH₂)  ← recycled

---

Deficiency

Causes

1. Poor dietary intake alone — rare (gut bacteria supplement dietary supply)
2. Antibiotic therapy — destroys gut flora → reduced K₂ synthesis; especially dangerous when combined with poor oral intake (ICU patients)
3. Fat malabsorption — obstructive jaundice (no bile salts), celiac disease, short bowel syndrome, IBD, cystic fibrosis
4. Total Parenteral Nutrition (TPN) — without vitamin K supplementation
5. Newborns — sterile gut (no bacteria); breast milk provides only ~⅕ of daily requirement → Hemorrhagic Disease of the Newborn (HDN)
6. Warfarin/Coumarin therapy — competitive VKOR antagonism
7. Certain cephalosporins (e.g., cefamandole) — warfarin-like VKOR inhibition

Consequences

• Bleeding diathesis (hypoprothrombinemia)
• Prolonged PT (most sensitive — Factor VII has shortest half-life, extrinsic pathway)
• Prolonged aPTT (intrinsic pathway factors IX, X affected)
• Undercarboxylated prothrombin must fall >50% before PT elevates
• Possible osteoporosis (loss of osteocalcin function)
• Vascular calcification (loss of MGP function)

Lab Tests in Deficiency

---

Hemorrhagic Disease of the Newborn (HDN)

• Newborns have sterile intestines → no K₂ synthesis
• Breast milk poor in vitamin K
• Presents: bleeding from umbilical stump, skin, GI tract, intracranial hemorrhage (late HDN)
• Prevention: Single IM dose of vitamin K₁ (phytomenadione, 1 mg) at birth — standard of care

---

Warfarin and Vitamin K — Antagonism

---

Toxicity

• Natural K₁ and K₂: No established Upper Limit (UL) — no known toxicity
• K₃ (Menadione — synthetic): Prolonged large doses → hemolytic anemia + jaundice in infants (toxic effects on RBC membrane) → no longer used therapeutically

---

Clinical Uses of Vitamin K

1. Reversal of warfarin anticoagulation (supratherapeutic INR)
2. Prevention of HDN — IM vitamin K at birth
3. Liver disease with coagulopathy — trial of vitamin K to assess hepatic synthetic function
4. Malabsorption-related coagulopathy — parenteral vitamin K (10 mg SC daily)
5. Cephalosporin-associated hypoprothrombinemia — supplementation

For supratherapeutic INR (4.5–10.0) without active bleeding — stopping warfarin alone is usually sufficient; vitamin K administration provides no added benefit.

---

High-Yield Summary Points

---